Monofunctional Platinum(II) Anticancer Agents
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these d...
Main Authors: | Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/2/133 |
Similar Items
-
Synthesis and Characterisation of Platinum(II) Diaminocyclohexane Complexes with Pyridine Derivatives as Anticancer Agents
by: Brondwyn S. McGhie, et al.
Published: (2023-12-01) -
RNA-Seq Analysis of Cisplatin and the Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell Lung Cancer and IMR90 Lung Fibroblast Cell Lines
by: Jerry D. Monroe, et al.
Published: (2020-12-01) -
Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
by: Jaewan Jeon, et al.
Published: (2021-05-01) -
Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells
by: Sebastian W. Schleser, et al.
Published: (2023-07-01) -
Research Progress of Metal Anticancer Drugs
by: Yun Bai, et al.
Published: (2023-12-01)